Carbon footprint of severe asthma exacerbation management relative to Breezhaler dry powder inhaler

K. Beeh (Wiesbaden, Germany), S. Aumônier (Oxford, United Kingdom), A. Whiting (Oxford, United Kingdom), B. Fulford (Basel, Switzerland), K. Mezzi (Basel, Switzerland)

Source: Virtual Congress 2021 – Environment and respiratory health
Session: Environment and respiratory health
Session type: Oral Presentation
Number: 102

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Beeh (Wiesbaden, Germany), S. Aumônier (Oxford, United Kingdom), A. Whiting (Oxford, United Kingdom), B. Fulford (Basel, Switzerland), K. Mezzi (Basel, Switzerland). Carbon footprint of severe asthma exacerbation management relative to Breezhaler dry powder inhaler. 102

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Improving inhalation parameters through dry powder inhalers (DPIs) after an acute asthma exacerbation
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012


Handling and patient preference of dry powder inhalers for asthma and COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 210s
Year: 2006

Computerized measurements of inhalation ability with a dry powder inhaler in patients with severe COPD
Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more
Year: 2020


Inhaler treatment options in COPD
Source: Eur Respir Rev 2005; 14: 102-108
Year: 2005



Effect of switching from salmeterol/fluticasone dry powder inhaler to formoterol/fluticasone pressurized metered-dose inhaler in elderly asthma patients
Source: International Congress 2016 – Asthma management
Year: 2016


Inhaler choice in primary practice
Source: Eur Respir Rev 2005; 14: 117-122
Year: 2005



A novel NEXT DPI® dry powder inhaler and its use in asthmatic and COPD population
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Comparison of two dry powder inhalers containing budesonide in the treatment of asthma in children
Source: Eur Respir J 2002; 20: Suppl. 38, 500s
Year: 2002

The investigation of inhalation continuous duration for dry powder inhalers in asthmatic patients
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012


Dose delivery characteristics of two dry powder inhalers in COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 291s
Year: 2004

Utility of inhaled corticosteroids (fluticasone/formoterol) by pressurized metered-dose inhaler for the early management of acute exacerbations of asthma
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010

Use of dry powder inhalers in COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 286s
Year: 2005

Broncho dilator response to salbutamol delivered by metered dose inhaler with spacer versus dry powder inhaler in acute asthma in children
Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Year: 2016

Peak inspiratory flow rates through placebo dry powder inhaler device in various asthma and COPD patients
Source: Annual Congress 2012 - Asthma management
Year: 2012


Acceptability of two dry powder inhalers in 645 asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 338s
Year: 2005

Formoterol delivered by multi-dose dry powder inhaler (MDDPI) improves nocturnal asthma symptoms
Source: Eur Respir J 2005; 26: Suppl. 49, 50s
Year: 2005

One-year height growth in children with asthma treated with inhaled budesonide delivered from a new dry powder inhaler.
Source: Annual Congress 2008 - Clinical aspects of asthma in school-aged children
Year: 2008

Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage versus a dry powder inhaler in moderate to severe asthmatic patients
Source: Eur Respir J 2003; 22: Suppl. 45, 284s
Year: 2003

Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 260s
Year: 2004

Oral manifestations in asthmatic patients using metered dose inhaler and dry powder inhaler
Source: International Congress 2019 – Innovations in primary care assessment and management
Year: 2019